Objective： To observe the pharmacokinetic process of cefaclor in 8 healthy volunteers and assess the bioequivalence between 2 kinds of its dosage forms. Methods： A randomized crossover and self-control design was used. Eight healthy volunteers were single oral dosed with 250 mg dispersing tablet or capsule, respectively. The plasma and urine concentrations were determined by HPLC method. The pharmacokinetic parameters were calculated by 3P87 program and the bioequivalence was assessed by ANOVA. Results：A one-compartment open pharmacokinetic model was adopted and the cmax, tmax, t1/2 and AUC0？∞ of tablet and capsule were (15.87±4.54) and (13.75±4.54) μg/ml; (0.63±0.19) and (0.66±0.19) h; (0.54±0.13) and (0.63±0.20) h; (19.13±2.82) and (18.30±3.62) h*μg/ml. There were no significant differences between the 2 preparations. Conclusion：The 2 kinds of preparations are bioequivalent and the average relative bioavailability of dispersing tablet is (106.59±19.13)%.